Dr. Francis Discusses the SOFT Trial for Breast Cancer

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.

The updated results have a median 8 years of follow-up. There is statistically significant improvement in disease-free survival following this longer follow-up. In the high-risk patients who received chemotherapy, there are overall survival advantages in this group of patients, which needs to be investigated further.